Drug General Information
Drug ID	D04CJE
Former ID	DIB007768
Drug Name	ATF-936
Indication	Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890]		Phase 1	[531447]
Company	Novartis AG
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Extracellular calcium-sensing receptor	Target Info	Antagonist	[531447]
Pathway Interaction Database	E-cadherin signaling in keratinocytes
Reactome	G alpha (q) signalling events
	G alpha (i) signalling events
	Class C/3 (Metabotropic glutamate/pheromone receptors)
WikiPathways	GPCRs, Class C Metabotropic glutamate, pheromone
	Gastrin-CREB signalling pathway via PKC and MAPK
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 531447	ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41.
Ref 531447	ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.